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Abstract Background: Nivolumab, a monoclonal antibody of immune checkpoint pro-
grammed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the
one hand and nivolumab as monotherapy on the other, have both demonstrated improved ef-
ficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combina-
tion resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in
diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for pa-
tients with advanced melanoma in clinical trial CheckMate 067.
Patients and methods: HRQoL was assessed at weeks 1 and 5 per 6-week cycle for the first
6 months, once every 6 weeks thereafter, and at two follow-up visits using the European Organi-
zation for Research and Treatment of Care Core Quality of Life Questionnaire and the EuroQoL
Five Dimensions Questionnaire. In addition to the randomised population, patient subgroups,
including BRAF mutation status, partial or complete response, treatment-related AEs of grade
3/4, and those who discontinued due to any reason and due to an AE, were investigated.
Results: Nivolumab and ipilimumab combination and nivolumab alone both maintained
HRQoL, and no clinically meaningful deterioration was observed over time compared with ipili-
mumab. In addition, similar results were observed across patient subgroups, and no clinically
meaningful changes in HRQoL were observed during follow-up visits for patients who discontin-
ued due to any cause.
Conclusion: These results further support the clinical benefit of nivolumabmonotherapyandnivo-
lumab and ipilimumab combination therapy in patients with advanced melanoma. The finding
that the difference in grade 3/4 AEs between the arms did not translate into clinically meaningful
differences in the reported HRQoL may be relevant in the clinical setting.
Study number: NCT01844505.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The treatment of advanced melanoma has progressed
considerably with the introduction of T-cell checkpoint
inhibitors, including inhibitors of cytotoxic T-lympho-
cyte antigen 4 (CTLA-4) and programmed death 1
(PD-1) [1e4]. An antibody to CTLA-4, ipilimumab,
improved the overall survival (OS) of patients with
advanced melanoma in two phase III, randomised
controlled trials [1,5]. The PD-1 inhibitors nivolumab
and pembrolizumab have shown improved progression-
free survival (PFS) and OS compared with ipilimumab
[3,4,6]; in addition, nivolumab has shown improved PFS
and OS compared with chemotherapy [2].
Combination treatment with nivolumab plus ipili-
mumab has shown considerable efficacy across clinical
trials [4,6e9], including the phase II CheckMate 069
study and the phase III CheckMate 067 study in patients
with untreated advanced melanoma, with objective
response rates of 59% and 58%, respectively, for the
combination and 11% and 19%, respectively, for ipili-
mumab alone [4,8]. In addition, 2-year OS for the
combination compared with ipilimumab alone was 64%
versus 54% [9] and 64% versus 45% [6].
The greater efficacy of combined checkpoint in-
hibitors is accompanied by higher incidence of grade 3
and 4 adverse events (AEs) versus either agent alone. In
CheckMate 069, treatment-related grade 3/4 AEs were
reported in 54% of patients who received combination
and 20% of patients who received ipilimumab alone [9];
for CheckMate 067, the percentages were 55% and 27%,
respectively [4]. This toxicity profile might diminish
health-related quality of life (HRQoL). Patient-reported
outcomes (PROs), such as symptoms, HRQoL, and
patient-perceived health status supplement clinical data
and are now more important during decision-making in
oncology because they provide a holistic understanding
of patient experience and treatment effectiveness [10,11].
Ipilimumab monotherapy did not have a significant
negative HRQoL impact in patients with stage III or IV
melanoma [12], and nivolumab monotherapy main-
tained baseline HRQoL levels compared with dacarba-
zine in patients with advanced melanoma [13]. Here we
report analyses of HRQoL for patients with advanced
melanoma treated with nivolumab plus ipilimumab,
nivolumab alone, or ipilimumab alone in CheckMate
067. In addition to the full HRQoL patient population,
we examined subgroups including patients with BRAF
mutation status, patients with a partial or complete
response, patients with treatment-related AEs of grade 3
or 4, and patients who discontinued due to any reason
and those who discontinued due to an AE.
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2. Patients and methods
2.1. Study design
This study presents 12-month HRQoL data from the
067 CheckMate double-blind, phase III study; study
details have been published [4]. Briefly, patients
aged  18 years with histologically confirmed stage III
(unresectable) or stage IV melanoma with no prior
systemic treatment for advanced disease were rando-
mised 1:1:1 and stratified by programmed cell death
ligand 1 (PD-L1) status, BRAF status, and metastatic
stage. Patients received one of the following by intra-
venous infusion, with the appropriate placebo: nivolu-
mab 3 mg/kg every 2 weeks (Q2W); nivolumab 1 mg/kg
Q3W plus ipilimumab 3 mg/kg Q3W for 4 doses, fol-
lowed by nivolumab 3 mg/kg Q2W; or ipilimumab
3 mg/kg Q3W for 4 doses. Treatment was continued
until disease progression, development of unacceptable
toxic events, or withdrawal of consent. Per investigator,
patients with clinical benefit and without substantial
AEs could be treated beyond progression.
2.2. Assessments
HRQoL was collected, as available, in all randomised
patients and assessed at weeks 1 and 5 of each 6-week
cycle for the first 6 months and then once every 6 weeks
thereafter as well as at two visits in the follow-up period
(Fig. A.1). Secondary end-point assessment was Euro-
pean Organisation for Research and Treatment of
Cancer (EORTC) QLQ-C30 Questionnaire Version 3
[14,15]; European Quality of Life-5 Dimensions (EQ-
5D) Summary Index and Visual Analogue Scale (VAS)
[16,17] and the Work Productivity and Activity
Impairment: General Health (WPAI:GH) were explor-
atory end-points [18]. WPAI:GH analyses were not
included in this report because they only include patients
in the workforce and the number of patients was too low
for adequate analysis.
2.3. Statistical analyses
Analyses were performed on all randomised patients
with both a baseline and  1 post-baseline assessment.
Analyses were also performed on subgroups including
patients with BRAF mutation status, patients with a
partial or complete response, and patients with AEs of
grade 3 or 4. In addition, follow-up data were analysed
for patients who discontinued due to any reason and
those who discontinued due to an AE. For each in-
strument, the questionnaire completion rate was defined
as the proportion of patients who completed the ques-
tionnaire at the indicated time point using the number of
patients in the study at the respective time point as the
denominator. It was predetermined that conclusions
would only be drawn from time points for which  30
patients completed assessments.
Continuous data were described using descriptive
statistics, and categorical data were summarised using
counts and percentages. Mean changes from baseline at
each time point were reported and assessed according to
minimally important difference (MID) values, with
statistical significance assessed at P  0.05. The EORTC
QLQ-C30 is a 30-item, self-administered, multidimen-
sional, cancer-specific, HRQoL PRO questionnaire,
with a difference of 10 points on a 100-point scale
considered clinically meaningful [19]. The EQ-5D-3L
descriptive system is composed of the five dimensions
of mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression with a utility index score differ-
ence of 0.08 considered clinically meaningful; the EQ-
5D VAS records the respondent’s self-rated health on
a vertical VAS with a score of 7 considered clinically
meaningful [20].
To assess longitudinal changes from baseline within
and between each treatment, modelling was conducted
using all observed data through week 55 via a mixed-
effects model for repeated measures (MMRM),
including baseline PRO score and stratification factors
as covariates. MMRM can give unbiased estimates with
certain missing data contexts and can be more
powerful than a two-sample t-test [21]. Least squares
(LS) means and standard error (SE) as well as LS means
difference with 95% confidence interval (CI) were
calculated for nivolumab versus ipilimumab and for
nivolumab þ ipilimumab combination versus ipilimu-
mab alone. Estimates were based on a mixed model with
treatment and time point as fixed effects, study day as a
random effect, and time point as a repeated measure.
Values were imputed for missing items for the
EORTC QLQ-C30 by using values equal to the average
of the non-missing items for scales in which at least half
of the items were completed. A scale in which fewer than
half of the items were completed was treated as missing
and, once the instrument was scored, no imputation was
used to handle missing data. No adjustment was made
for missing data when scoring the EQ-5D index or the
EQ-5D VAS and no imputation was used to handle
missing data for the longitudinal analysis.
Analyses were conducted using SAS version 9.4 (SAS
Institute, Cary, NC).
3. Results
3.1. Baseline characteristics and questionnaire completion
rates
The study conducted at 137 sites in 21 countries had an
enrolment period from June 2013 to March 2014 [4]. Of
the 1296 patients enrolled, 945 were randomised: 316 to
nivolumab (313 treated), 314 to nivolumabþ ipilimumab
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(313 treated), and 315 to ipilimumab (311 treated).
HRQoL outcomes were performed on all 803 randomised
patients with both a baseline and at least one post-baseline
assessment (HRQoL randomised population; Table 1).
Baseline demographics and disease characteristics were
similar among the treatment groups and to themain study
all-randomised-patients group (Table 1) [4].
Questionnaires were completed over a maximum of
79 weeks as well as two follow-up visits following
treatment discontinuation (Table 2). Completion rates
for the EORTC QLQ-C30 at baseline plus 1
visit were 85.1% for nivolumab, 87.3% for
nivolumab þ ipilimumab, and 82.2% for ipilimumab.
Completion rates for the EQ-5D-3L at baseline plus 1
visit were 84.5% for nivolumab, 87.3% for
nivolumab þ ipilimumab, and 81.9% for ipilimumab. At
each time point through week 67, completion rates
remained 50% for both questionnaires. Of the 383
patients who progressed in the first 4 months, 69 (54%)
in the nivolumab group, 38 (46%) in the
nivolumab þ ipilimumab group, and 97 (56%) in the
ipilimumab group had follow-up PRO data. Analysis
conclusions were drawn from time points for which 30
patients completed assessments. Although overall
completion rates for WPAI:GH were similar to EORTC
QLQ-C30 and EQ-5D-3L, ranging from 80.6% to 86.3%
at baseline, completion rates for individual subsections
at baseline were very low, including percentage of work
time missed (28.9e30.4%), percentage of impairment
while working (21.9e24.0%), and percentage of overall
work impairment (21.9e23.7%).
3.2. HRQoL randomised population analyses
Changes from baseline for EORTC QLQ-C30 are
shown in Fig. 1A. Slight deterioration from baseline
started at week 5 and showed an overall trend toward
stabilization from week 25. No clinically meaningful
changes were observed in any treatment group while on
treatment. Clinically meaningful deterioration was
observed at week 7 for nivolumab þ ipilimumab for role
functioning as well as the fatigue and appetite loss
symptom scales (data not shown).
Changes from baseline for EQ-5D utility index are
shown in Fig. 1B and for EQ-5D VAS in Fig. 1C. No
clinically meaningful changes were observed in any
group while on treatment in any time point.
3.3. MMRM results for benefit assessment
Longitudinal modelling was performed using all
observed data for patients remaining in the study
through week 55 including baseline PRO and stratifi-
cation factors as covariates. Table A.1 shows the LS
means and SE for nivolumab versus ipilimumab and for
nivolumab versus nivolumab þ ipilimumab across the
Table 1
Characteristics of patients at baseline.
Patient-reported outcome population Overall study [4]
Nivolumab
(n Z 270)
Nivolumab þ ipilimumab
(n Z 274)
Ipilimumab
(n Z 259)
Overalla
(n Z 803)
Total
(N Z 945)
Age
Mean (SD) 58.9 (13.2) 59.2 (14.0) 60.7 (13.2) 59.6 (13.5) 60 (13.7)
Sex, n (%)
Male 173 (64.1) 183 (66.8) 167 (64.5) 523 (65.1) 610 (64.6)
Female 97 (35.9) 91 (33.2) 92 (35.5) 280 (34.9) 335 (35.4)
ECOG performance status score, n (%)
0 209 (77.4) 207 (75.5) 186 (71.8) 602 (75.0) 692 (73.2)
1 61 (22.6) 67 (24.5) 73 (28.2) 201 (25.0) 252 (26.7)
Metastasis stage, n (%)
M0/M1a/M1b 114 (42.2) 116 (42.3) 111 (42.9) 341 (42.5) 397 (42.0)
M1c 156 (57.8) 158 (57.7) 148 (57.1) 462 (57.5) 548 (58.0)
Lactate dehydrogenase status, n (%)
ULN 172 (63.7) 181 (66.1) 167 (64.5) 520 (64.8) 589 (62.3)
>ULN 94 (34.8) 93 (33.9) 90 (34.7) 277 (34.5) 341 (36.1)
Missing 4 (1.5) 0 2 (0.8) 6 (0.7) 15 (1.6)
Brain metastases, n (%)
Yes 6 (2.2) 9 (3.3) 9 (3.5) 24 (3.0) 34 (3.6)
No 264 (97.8) 265 (96.7) 250 (96.5) 779 (97.0) 911 (96.4)
BRAF mutation status, n (%)
Mutation 83 (30.7) 93 (33.9) 84 (32.4) 260 (32.4) 298 (31.5)
Wild type 187 (69.3) 181 (66.1) 175 (67.6) 543 (67.6) 647 (68.5)
PD-L1 status, n (%)
Positive 126 (46.7) 126 (46.0) 120 (46.3) 372 (46.3) 223 (23.6)
Negative 144 (53.3) 148 (54.0) 139 (53.7) 431 (53.7) 620 (65.6)
a Based on patients who had both baseline and at least one post-baseline HRQoL assessment.
ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; ULN, upper limit of normal.
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longitudinal model through week 55, as well as the dif-
ference in LS means between treatment arms with 95%
CIs. No clinically meaningful changes were observed
based on MID within any treatment arm for EORTC
QLQ-C30 or EQ-5D.
3.4. Subgroup analyses
Fig. 2 shows changes from baseline for all 3 HRQoL
outcomes for randomised patients with BRAF mutation
(left) and BRAF wild type (right). A clinically mean-
ingful decline was observed in the BRAF mutation
subgroup with ipilimumab treatment at weeks 11 and 13
in the EQ-5D VAS and a clinically meaningful
improvement in the BRAF wild-type subgroup for
nivolumab at weeks 31e37. No other clinically mean-
ingful changes were observed at any other time point.
Changes from baseline for all three HRQoL out-
comes for randomised patients with either complete or
partial response are shown in Fig. 3 (left). A clinically
Table 2
Patient-reported outcome completion rates.a
Patients, n/N (%) Nivolumab (n Z 316) Nivolumab þ ipilimumab
(n Z 314)
Ipilimumab (n Z 315)
EORTC QLQ-C30
Baselineb 284/316 (89.9) 290/314 (92.4) 279/315 (88.6)
Baseline plus 1 269/316 (85.1) 274/314 (87.3) 259/315 (82.2)
Week 5 228/302 (75.5) 182/293 (62.1) 220/300 (73.3)
Week 7 237/291 (81.4) 182/276 (65.9) 217/291 (74.6)
Week 11 198/271 (73.1) 113/226 (50.0) 163/244 (66.8)
Week 13 193/249 (77.5) 106/201 (52.7) 129/205 (62.9)
Week 17 156/220 (70.9) 83/164 (50.6) 103/158 (65.2)
Week 19 164/205 (80.0) 97/155 (62.6) 98/144 (68.1)
Week 23 133/188 (70.7) 87/137 (63.5) 76/118 (64.4)
Week 25 142/182 (78.0) 97/130 (74.6) 74/111 (66.7)
Week 31 121/164 (73.8) 92/125 (73.6) 50/87 (57.5)
Week 37 112/152 (73.7) 90/119 (75.6) 48/75 (64.0)
Week 43 100/145 (69.0) 74/114 (64.9) 44/65 (67.7)
Week 49 92/128 (71.9) 65/97 (67.0) 40/58 (69.0)
Week 55 63/100 (63.0) 48/72 (66.7) 24/43 (55.8)
Week 61 38/58 (65.5) 29/42 (69.0) 17/28 (60.7)
Week 67 13/21 (61.9) 16/22 (72.7) 9/13 (69.2)
Week 73 3/4 (75.0) 6/9 (66.7) 0/2 (0)
Week 79 e 2/2 (100.0) 1/2 (50.0)
Follow-up 1c 96/104 (92.3) 105/108 (97.2) 124/136 (91.2)
Follow-up 2c 58/62 (93.5) 96/99 (97.0) 97/103 (94.2)
EQ-5D
Baselineb 282/316 (89.2) 290/314 (92.4) 278/315 (88.3)
Baseline plus 1 267/316 (84.5) 274/314 (87.3) 258/315 (81.9)
Week 5 227/302 (75.2) 180/293 (61.4) 218/300 (72.7)
Week 7 237/291 (81.4) 182/276 (65.9) 216/291 (74.2)
Week 11 198/271 (73.1) 113/226 (50.0) 163/244 (66.8)
Week 13 193/249 (77.5) 106/201 (52.7) 129/205 (62.9)
Week 17 156/220 (70.9) 83/164 (50.6) 103/158 (65.2)
Week 19 163/205 (79.5) 97/155 (62.6) 97/144 (67.4)
Week 23 133/188 (70.7) 87/137 (63.5) 76/118 (64.4)
Week 25 142/182 (78.0) 97/130 (74.6) 74/111 (66.7)
Week 31 121/164 (73.8) 92/125 (73.6) 50/87 (57.5)
Week 37 112/152 (73.7) 89/119 (74.8) 48/75 (64.0)
Week 43 100/145 (69.0) 74/114 (64.9) 44/65 (67.7)
Week 49 92/128 (71.9) 65/97 (67.0) 40/58 (69.0)
Week 55 63/100 (63.0) 48/72 (66.7) 24/43 (55.8)
Week 61 38/58 (65.5) 29/42 (69.0) 17/28 (60.7)
Week 67 13/21 (61.9) 16/22 (72.7) 9/13 (69.2)
Week 73 3/4 (75.0) 6/9 (66.7) 0/2 (0)
Week 79 e 2/2 (100.0) 1/2 (50.0)
Follow-up 1c 96/104 (92.3) 105/108 (97.2) 124/136 (91.2)
Follow-up 2c 58/62 (93.5) 96/99 (97.0) 97/103 (94.2)
a Completion rate is calculated using the number of patients with non-missing PRO data at baseline and data from  1 post-baseline visit,
divided by the number of patients in the study at each respective time point.
b Baseline completion rate based on subjects having any baseline data with no post-baseline data requirement.
c Follow-up visit 1Z 30 d from the last dose (  7 d) or coinciding with the date of discontinuation ( 7 d) if date of discontinuation is greater
than 37 d after last dose; follow-up visit 2 Z 84 d (  7 d) from follow-up visit 1.
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meaningful decline was observed with the ipilimumab
treatment group for the EQ-5D VAS at week 19. No
other clinically meaningful changes were observed.
Changes from baseline for all three HRQoL outcomes
for randomised patients with a grade 3 or 4 AE are shown
in Fig. 3 (right panels). Clinically meaningful declines
were observed in the early weeks with ipilimumab in the
EQ-5D VAS outcome and with nivolumabþ ipilimumab
in the EORTC QLQ-C30 at week 17. No other clinically
meaningful changes were observed, although the nivolu-
mab group had borderline improvement in the EQ-5D
utility index from weeks 37e43.
Fig. 4 shows changes from baseline (last measurement
before discontinuation) to follow-up visits 1 and 2 for all
three HRQoL outcomes for patients who discontinued
for any reason (left) or due to an AE (right). No clinically
meaningful changes were observed in any of the three
assessments for patients who discontinued for any
reason. Due to low patient numbers in other groups of
patients who discontinued due to an AE, conclusions can
only be drawn for the nivolumab þ ipilimumab group.
For this group, a clinically meaningful decline was
observed only in the EQ-5DVAS assessment at follow-up
visits 1 and 2.
3.5. HRQoL combined with response rate and grade 3/4
AEs
To observe response rate and grade 3/4 AEs with regard
to HRQoL, we created an overlay of the randomised
population EORTC QLQ-C30 with best overall
response (BOR) at 6 months and 12 months for the 3
treatment groups, along with percentage of grade 3/4
AEs at 11 weeks, 6 months, and 12 months for the three
treatment groups (Fig. A.2). Differences in BOR and
grade 3/4 AEs between the arms do not seem to correlate
with EORTC QLQ-C30.
4. Discussion
Nivolumab alone and combined with ipilimumab have
both demonstrated improved efficacy compared with
ipilimumab alone in the CheckMate 067 study, although
the combination resulted in a higher frequency of grade
3/4 AEs [4]. Here we show that nivolumab þ ipilimumab
and nivolumab alone maintained HRQoL and no dete-
rioration was observed over time compared with ipili-
mumab. In addition, similar results were observed across
patient subgroups including BRAF mutation status, pa-
tients with complete and partial responses, and patients
with grade 3 or 4 AEs over time. In the main scale
analyses, no clinically meaningful changes were detected
for either nivolumab or nivolumabþ ipilimumab around
the week 12 time point (first staging for these patients).
In addition, no changes in HRQoL were observed during
Fig. 1. Change in baseline in HRQoL for total quality-of-life
population. Mean (SD) EORTC QLQ-C30 global health score
(A) at baseline was 74.7 (19.4) for nivolumab, 70.7 (22.3) for
nivolumab þ ipilimumab, and 73.5 (20.5) for ipilimumab; mean
(SD) EQ-5D utility index score (B) at baseline was 0.803 (0.219)
for nivolumab, 0.779 (0.234) for nivolumab þ ipilimumab, and
0.791 (0.226) for ipilimumab; mean (SD) EQ-5D VAS score (C)
at baseline was 75.9 (18.5) for nivolumab, 74.0 (19.9) for
nivolumab þ ipilimumab, and 75.8 (18.3) for ipilimumab. Clin-
ical significance (denoted by the horizontal dashed line at these
points) was determined by the MID value for each test, which
was 10 points for EORTC QLQ-C30, 0.8 points for EQ-
5D utility index, and 7 points for EQ-5D VAS. SD, standard
deviation.
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follow-up visits for patients who discontinued due to any
cause; for patients who discontinued due to an AE,
clinically meaningful declines were only observed for one
of the three assessments.
Patient-focussed care is becoming a more critical
component of quality health care [22]. Specifically,
PROs are more prominent and were used in 27% of
clinical trials registered from November 2007 to
December 2013 [11]. Moreover, an initiative has been
established to provide recommendations on analysis
standardization of HRQoL and other PROs in rando-
mised cancer trials [10].
Fig. 2. Change in baseline in HRQoL for BRAF mutation status subgroup. Clinical significance (denoted by the horizontal dashed line at
these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30 (A, B), 0.8 points for EQ-5D
utility index (C, D), and 7 points for EQ-5D VAS (E, F).
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Investigating HRQoL is important for immune
checkpoint inhibitors because of the associated toxicity
profile. In this study, HRQoL stayed within ranges
defined as MID in the EORTC QLQ-C30, EQ-5D utility
index, and EQ-5D VAS assessments, including across
various subgroups of patients. HRQoL has also been
better maintained by pembrolizumab than by chemo-
therapy in a phase II study in patients with ipilimumab-
Fig. 3. Change in baseline in HRQoL for patient response and AEs subgroups. Clinical significance (denoted by the horizontal dashed line
at these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30 (A, B), 0.8 points for EQ-5D
utility index (C, D), and 7 points for EQ-5D VAS (E, F).
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refractory melanoma [23]. Combined targeted therapy
of BRAF inhibitors and mitogen-activated protein ki-
nase kinase enzymes MEK1 and/or MEK2 (MEK) in-
hibitors is another treatment for advanced melanoma.
The addition of trametinib to dabrafenib in a phase III
trial in patients with metastatic melanoma and the
BRAF V600 mutation did not result in patient dete-
rioration of HRQoL and, in fact, improved EORTC
QLQ-C30 scores compared with dabrafenib mono-
therapy [24]. Similar results were observed in a phase III
Fig. 4. Change in baseline in HRQoL for patients who discontinued therapy for any cause or due to an AE. Clinical significance (denoted
by the horizontal dashed line at these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30
(A, B), 0.8 points for EQ-5D utility index (C, D), and 7 points for EQ-5D VAS (E, F).
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open-label trial for the combination of dabrafenib plus
trametinib compared with vemurafenib in patients with
BRAF V600 metastatic melanoma [25].
Of note, the marked difference in the rate of grade 3/4
AEs observed in the three arms (nivolumabþ ipilimumab
[58.5%], nivolumab [20.8%], and ipilimumab [27.7%] [6])
did not translate into a clinically meaningful difference in
HRQoL. This may be due to several factors, for example,
HRQoL may be driven by anxiety and willingness to
survive at treatment start, thereby neutralising the nega-
tive perception of AEs. Also, the instruments used to
assess HRQoL are designed for patients treated with
chemotherapy and may not detect the impact of the AEs
observed with immunotherapy. Lastly, patient numbers
were low in both the later weeks of analysis, and within
some of the subgroups analysed, thus limiting the inter-
pretation of the results. Using these results, one could
conclude that nivolumab þ ipilimumab does not seem to
be limited by HRQoL considerations, however, trial
populations may differ from the ‘real-world’ patient with
melanoma in terms of motivation, the likelihood of PRO
reporting, and the ability to withstand treatment-related
AEs.
Along with OS and PFS, quality-of-life measures
have been included for use in the European Society for
Medical Oncology Magnitude of Clinical Benefit Scale
(ESMO-MCBS) [26]. This scale, proposed to be a
standardised validated approach to stratify the magni-
tude of clinical benefit anticipated from anticancer
therapies, will be used to emphasise treatments in the
ESMO guidelines. The CheckMate 067 study demon-
strated improved efficacy, and has now shown stable
HRQoL for multiple assessments.
In conclusion, HRQoL was maintained in all treat-
ment groups with little clinically meaningful changes
noted in EORTC QLQ-C30, EQ-5D utility index, and
EQ-5D VAS assessments. Similar results were observed
across patient subgroups including BRAF mutation sta-
tus, patients with complete and partial responses, and
patients with grade 3 or 4 AEs over time, as well as during
follow-up visits for patients who discontinued due to any
cause. These results further support the clinical benefit of
nivolumab monotherapy and nivolumab þ ipilimumab
combination therapy over ipilimumab monotherapy in
patients with advanced melanoma.
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